Insilico to present at the WuXi Healthcare Forum 2019

IMAGE

Credit: Insilico Medicine

Tuesday, February 26, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in Artificial Intelligence for Aging Research and Productive Longevity at the WuXi Healthcare Forum 2019 in the section titled “The new wave: Anti-Aging” in Shanghai, on March 5.

Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in studying the biology of aging on many levels. The discussion will focus on the new frontiers in the biology of aging and the future of longevity science. Another major point of discussion is how technology and industry collaborations can drive successful outcomes in longevity science.

“We are happy to present our latest research at the WuXi AppTec HealthCare Forum, which gathers the leading longevity scientists and investors. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area”, says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.

“We at AAIH commend WuXi for recognizing the growing importance of artificial intelligence in improving healthcare for the global community as China has become a key player in the development of new, cutting-edge medical therapies. We are also very pleased that AAIH board director Dr. Alex Zhavoronkov of member company Insilico Medicine will have the opportunity to speak directly to the Wuxi Forum audience about the future benefits and issues associated with AI in healthcare”, said Annastasiah Mudiwa Mhaka, PhD., President of AAIH.

WuXi Healthcare Forum 2019 provides unparalleled access to the industry’s most respected movers and shakers – delivered through two days of visionary keynotes, country-specific tracks, 200 intimate CEO roundtables, private 1-1 coaching, and a world of collaborative opportunities. The event will take place on March 5-6 in Shanghai, one of the most dynamic cities in the world, full of spirit, innovation, and cultural splendor.

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

For further information, images or interviews, please contact:

Contact: Klug Gehilfe

[email protected]

Website: http://insilico.com/

Conference Official Website :

WuXi Healthcare Forum 2019

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Media Contact
Klug Gehilfe
[email protected]

Comments